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Purpose

Abstract

Our objectives were to 1) determine the difference in Rhabdomyosarcoma (RMS)
incidence and survival between different race/ethnicity groups, and 2) evaluate the
difference in survival of RMS between children and adults of these race/ethnicity
groups, using the Surveillance, Epidemiology, and End Results Program (SEER)
database between 1973-2013.
Patients and Methods
We analyzed racial characteristic and incidence data from 4,280 patients diagnosed
with RMS, between 1973-2013, that were reported to the SEER database. Survival and
hazard analyses were conducted on 4,268 patients with known follow-up data, with end
point being death from any cause.
Results
Over the 40-year study period overall RMS incidence rates have experienced a
statistically significant decline (APC: -0.78, 95% CI: -1.28 – -0.28). Whites have
experienced a significant decline in incidence rates (APC: -1.05, 95% CI: -1.60 – -0.50).
Though not statistically significant, incidence rates in Blacks and Hispanics have
trended upwards. While adjusted survival was not predicted by race, survival did
significantly differ among racial/ethnic groups in children, with Hispanics and “Others”
having the lowest 5- and 10-year survival rates (65% and 58% verses 58% and 56%,
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respectively). Black race/ethnicity was also shown to be a predictor for mortality for the
time period 1990-2013.
Conclusion
Racial/ethnic minorities have worse RMS clinical presentation and incidence rates than
Whites. While overall survival is not predicted by race, being an ethnic minority child
diagnosed with RMS is predictive of survival. These disparities point towards a genetic
component in RMS that has not yet been described.
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Introduction

!

While the annual incidence of Rhabdomyosarcoma (RMS) among those younger
than 20 years is 4.6 cases per million people [1,2], RMS is one of the most common
childhood and adolescent tumors, representing more than 50% of soft tissue sarcoma
cases in this age group [2,3], and nearly 3.4% of cancers overall [4]. Approximately 350
children and adolescents in the United States (US) are diagnosed with RMS per year,
with half of these cases occurring in patients under 10 years of age [1,2]. RMS can
occur in those older than 20, though it is exceedingly rare [3], accounting for only 3% of
soft-tissue sarcomas and less than 1% of cancers overall in this age group [4].
RMS is a rare, highly malignant soft tissue sarcoma that originates from the
embryonal mesenchyme [5,6], which imitates normal striated muscle tissue [7].
Although RMS tumors are typically found within striated muscle, they can occur virtually
anywhere in the body [6,7], excluding bone [8]. RMS is further classified as embryonal
(approximately 70% of cases), alveolar (approximately 30% of cases), pleomorphic,
spindle cell, mixed-type, and RMS not otherwise specified (NOS) histologic subtypes
[1,5], which makes it difficult to classify patients into homogenous treatment groups [8].
Due to the rarity of RMS, little is known about the etiology and epidemiology of this
disease [6].
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Collaborative pediatric trials from the Intergroup Rhabdomyosarcoma Study
Group (IRSG) have revolutionized the therapeutic methods for this sarcoma [8-10].
Based on the conclusions of these studies multimodality treatment regimens, involving
chemotherapy and/or radiation, are decided by tumor staging (based on tumor primary
site, tumor size, and the presence or absence of regional lymph node involvement and
of distant metastasis), grouping (defined by the amount of residual tumor after initial
surgery), and the histologic subtype of the tumor [8-10]. Pediatric patients with
nonmetastatic disease have received the most benefit from these studies, with cure
rates up to approximately 70% [3,5,11] from 25% in 1970 [5,11]. Prognosis in adults
with RMS is very poor, with overall survival rates of 20% to 40% [3,4] verses rates of
60% to 80% for children [4], calling into question whether or not chemotherapy (which is
a key feature in pediatric treatment) should be used at all in adults [3]. Unfortunately this
question is not easily answered, as large multi-institutional studies focusing on adult
RMS have not been conducted, and only small, single institution reports have been
published [3].
There are gaps in the literature involving regarding disparities in survival by race
or ethnicity for RMS, for both adults and children [3,4,11-17]. This is presumably due to
either limitations in the data prior to expansion of certain cancer registry programs, or as
a result of underrepresentation of certain populations in clinical trials for cancer [18].
Our objectives were to 1) determine the difference in RMS incidence and survival
between race/ethnicity groups, and 2) evaluate the difference in survival of RMS
between children and adults within these race/ethnicity groups, using the Surveillance,
Epidemiology, and End Results Program (SEER) database between 1973-2013.
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Methods
Data Source and Study Population
The November 2015 release of SEER program data [19] were analyzed to
evaluate incidence and survival rates of RMS in the United States between 1973 and
2013. The SEER Program collects information from population-based registries on
demographics, histology, tumor site, tumor stage at diagnosis, first course of treatment,
and vital status [19]. The SEER 18 Program is an expansion on two previous SEER
programs. The first, SEER 9, covered the states of Connecticut, Iowa, New Mexico,
Utah, and Hawaii; the metropolitan areas of Detroit, Atlanta, San Francisco-Oakland,
and Seattle-Puget Sound, starting in 1973 [19]. The next program, SEER 13, added
registries in 1992 in Los Angeles, San Jose-Monterey, Alaska Native Registry, and rural
Georgia, allowing for analysis on Hispanic populations [19]. The latest program, SEER
18, added Kentucky, Greater California, New Jersey, Louisiana, and Greater Georgia,
which increased program coverage to 30% of the US Population [19].
The study population for this analysis is all microscopically confirmed cases of
RMS. International Classification of Disease for Oncology, Third Edition (ICD-O-3)
morphology codes were analyzed to include the following RMS subtypes: 8900/3 (RMS,
NOS), 8901/3 (pleomorphic); 8902/3 (mixed type); 8910/3 (embryonal); 8912/3 (spindle
cell); and 8920/3 (aveolar). A total of 4,325 RMS patients were identified from the SEER
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data using the IDC-O-3 morphology codes. A total of 45 patients were excluded from
the analysis either because they had no microscopic confirmation of diagnosis or
diagnosis was confirmed by autopsy/death certificate only. After exclusion, 4,280
patients remained in the analysis. A total of 12 patients were further excluded due to
unknown survival time, leaving 4,268 patients in these analyses. A total of 30 patients
with localized/regional prostate SEER stage were recoded as regional stage. Patients
were further classified by age and diagnostic era. Pediatric patients are defined as
being 19 years or younger, and adults as 20 years or older. Diagnosis era was divided
into two categories: diagnosis in the period 1973 to 1989, and diagnosis in the period
1990 to 2013. This was done for two reasons: first, because results from two pediatric
clinical trials conducted by the IRSG [9,10] were made available, which revolutionized
how RMS is treated; and second because the addition of SEER 13 registries in 1992
expanded coverage, allowing for analysis of Hispanics [19]. Although SEER does not
directly collect information on Hispanic ethnicity, SEER does code Hispanic origin using
the North American Association of Central Cancer Registries (NAACCR) Hispanic
Identification Algorithm (NHIA), which uses surname and maiden name to determine
Hispanic ethnicity [19]. Race was coded as White, Black, Hispanic, and Other for this
analysis. After recoding for Hispanic ethnicity, 44 patients in the 1973 to 1989 diagnostic
era were further recoded from Hispanic ethnicity to “Other” because data on Hispanic
ethnicity in this era was not specifically collected until SEER 13 program expansion in
1992. Due to the rarity of RMS, and small cell counts, all other ethnicities (eg. American
Indian/AK Native, Asian/Pacific Islander, unknown, etc) were recoded as “Other”, in
both treatment eras, for the purposes of this analysis.
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International Classification of Disease for Oncology, Third Edition (ICD-O-3)
topography codes was used to define tumor primary site and tumor prognostic site.
Prognostic site was classified as favorable for tumors of the nonparameningeal head
and neck, the genitourinary system (excluding the kidney, bladder, and prostate), and
the biliary tract, and as unfavorable for all other sites. Tumor stage was classified using
the SEER staging system. Localized stage refers to an invasive tumor that is completely
confined to its organ of origin; regional stage refers to a tumor that has expanded
beyond its organ of origin, into surrounding tissues, and/or has spread to the regional
lymph nodes; distant stage refers to a tumor that has spread to distant organs and
tissue in remote parts of the body, and/or to distant lymph nodes [19].
This study was determined to be exempt from human research regulations by the
University of South Florida Institutional Review Board (IRB).
Statistical Analysis
Statistical Analyses were performed using SAS version 9.4 (SAS Institute, Cary,
NC). Frequency distributions, total and stratified by race, were calculated for categorical
variables, and means and standard deviations were calculated for continuous variables.
Associations between categorical variables were tested using Chi-Squared tests, with
an association deemed statistically significant if ! ! p-value<0.05. The effects of
demographic, pathologic, clinical, and treatment variables on survival were tested using
the univariate log-rank method for categorical variables. Multivariate analyses to test
significant prognostic factors (overall, by diagnostic era, by age, and by race) were
!
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conducted using the Cox proportional hazards regression. Cox modeling was further
performed to analyze racial survival rates, while adjusting for age category, sex,
diagnostic era, geographic region, histology, SEER stage of disease, primary tumor site
prognosis, and treatment. Kaplan-Meier survival estimates were used to construct racial
survival curves that were stratified by age category. Log-rank method was employed to
compare the survival curves.
SEER*Stat software (v. 8.3.2) was utilized to analyze incidence rates, trends,
and annual percentage change (APC). The SEER 9 population data was analyzed from
1973 to 2013 for Whites, Blacks, and Overall (all races), while the SEER 13 population
data was used to analyze the time period was 1992 to 2013 for Hispanics. All incidence
data were age-adjusted using the 2000 US Standard population and calculated per
100,000 person-years of follow-up. To determine the APC, the weighted least squares
method was used. P-values<0.05 were deemed statistically significant. Incidence rates
and APC were not analyzed for the race category Others due to limitations with the
SEER*Stat program.

!

6!

!

Results
Patient Characteristics
Of the 4,268 RMS patients included in this study, 2,427 (56.9%) were classified
as children (≤19 years) and 1,841 (43.1%) as adults. The median age of the entire
sample was 16 years (± 26.5 years, range: birth to 98 years). While Whites, Blacks, and
Others shared a similar median age to that of the overall, Hispanics had a lower median
age of 12 years (± 21.0 years). Males comprise majority of the sample, at 2,410 patients
(56.5%) verses females with 1,858 patients (43.5%). Significantly more patients were
diagnosed in the latter diagnostic period of 1990-2013 (3,371, 79.0%). More than half of
the RMS patients were diagnosed in the Western region (52.7%); however among
Blacks more than a third (37.2%) were diagnosed in the Southern region (Table 1).
Overall, Embryonal was the most common RMS histologic type with 1,698
(39.8%) patients, followed by RMS NOS (1,044, 24.5%), Alveolar (974, 22.8%),
Pleomorphic (395, 9.3%), Spindle Cell (85, 2.0%), and Mixed-type (72, 1.7%). Among
all races: Blacks were more likely to develop Embryonal RMS; Hispanics more likely to
develop Alveolar; and Whites more likely to develop RMS NOS. Regional metastasis
was found to be the most common SEER stage in the sample, with 1,271 patients
(29.8%), followed closely by localized (1,264, 29.6%), and distant disease (1,234,
28.9%). Although localized disease was the most frequent among Whites, compared to

!

7!

!
all races Blacks were more likely to develop localized disease. Distant disease was
found to be most common among each Blacks and Hispanics, with Hispanics being the
most likely to develop either regional or distant disease when compared to all races
(Table 1).
The most frequent tumor site for the entire sample was the head and neck,
excluding the orbit, with 1,073 patients (25.1%). Although the trunk was the most
common tumor site for Whites (767, 29.5%), Whites were more likely than any other
race to develop extremity tumors. Among Blacks, the most frequent tumor site was also
the trunk (173, 27.6%), and they were most likely race to develop genitourinary tumors.
Head and neck tumors were the most common tumor site among Hispanics (196,
29.5%), and were more likely to develop in Hispanics compared to all other races. In
this sample, majority of patients had an unfavorable primary tumor site (2,712, 63.5%).
For treatment, most patients received both radiation and surgery (1,300, 30.5%).
Hispanics and Others were more likely than Whites to receive no treatment or radiation
only. Whites were more likely than Blacks or Hispanics to receive surgery only, or both
radiation and surgery (Table 1).
Incidence and Annual Percentage Change
Across the entire study period, Whites had similar incidence rates to the overall
rate, Blacks had higher rates for majority of the study period, and Hispanics
experienced inconsistent rates (Figure 1). The overall APC for 1973 to 2013 is a
statistically significant decline of -0.78 (95% CI: -1.28 to -0.28). Whites also experienced
a statistically significant decline from 1973 to 2013, with an APC of -1.05 (95% CI: -1.60
to -0.50). Blacks had an increased 1973 to 2013 APC of 0.39 (95% CI: -0.74 to 1.53),
!

8!

!
though this increase was not statistically significant. Hispanics also experienced an
increased APC of 1.29 (95% CI: -1.33 to 3.97), from 1992-2013, that was not
statistically significant.
Survival Analysis
Survival for all races significantly dropped in the first 5 years, and then began to
level off (Figure 2). The log-rank p-value is 0.23, meaning that the survival curves do not
significantly differ and race is not a predictor of survival after adjustment for all other
variables in the model. Overall 5-year survival rate was 56%, the 15-year rate was 52%,
and the 30-year rate was 49%. For Whites the 5-, 15-, and 30-year survival rates were
57%, 53%, and 51%, respectively; for Blacks the rates were 53%, 49%, and 46%; for
Hispanics the rates were 56%, 52%, and 49%; and for Others the rates were 54%, 49%,
and 47%.
RMS survival by age, for each race is illustrated in Figure 3. The log-rank p-value
for the survival curves is <.0001, meaning there is a significant difference in survival
between children and adults. Child race categories Other and Hispanic had a
statistically significant lower survival rate than Whites and Blacks (p-value: 0.03). The 5, 15-, and 30-year survival rates were: for children overall 65%, 62%, and 59%,
respectively; for White children 66%, 63%, and 61%, respectively; for Black children
62% represents all three survival rates; for Hispanic children 65%, 58%, and a 39% 22year survival rate; for Other children 58%, 56%, and 56%, respectively. Adult race
categories Black, Other, and Hispanic had lower survival rates than Whites, although
this was not statistically significant (p-value: 0.21). The 5-, 15-, and 30-year survival
rates are: for adults overall 39%, 36%, and 33%, respectively; for White adults 42%,
!
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40%, and 35%; for Black adults 35%, 31%, and 31%, respectively; for Hispanic adults
30%, 26%, and 26% 18-year survival rate; and for Other adults 35%, 30%, and 30%,
respectively.
Univariate and Multivariate Analysis
!

Cox proportional hazard regression was performed for both the univariate and

multivariate analyses. In the univariate analysis (data not shown), adjusted for only age
at diagnosis and year of diagnosis, Black, Hispanic, and Other race served as
significant predictors for mortality. After inclusion of all variables in the multivariate
model, for the entire study period, race is no longer a predictor for mortality (Table 2).
Black race does trend towards significance with a hazard ratio (HR) of 1.14, and a pvalue of 0.06. Age at diagnosis, histologic type, SEER stage, and prognostic site all
serve as predictors for mortality when adjusted for all other variables in the model. Year
of diagnosis and treatment method served as protective factors in the model. When
stratified by year of diagnosis (Table 3), black race does become a significant predictor
of mortality (HR: 1.18, 95% CI: 1.01-1.38) in the model for diagnosis from 1990 to 2013.
Stratifying the model by age of diagnosis (Table 4), Other race becomes predictive in
children (HR: 1.31, 95% CI: 1.03-1.66). When stratified by race (Table 5), Black adults
have a higher HR of 2.86 (95% CI: 2.16-3.79) than adults of the other races. Blacks also
have higher HR’s in regional, distant, and unknown metastasis. Male sex is protective in
Hispanics (HR: 0.71, 95% CI: 0.55-0.91) in the stratified model. The race category
“Others” has higher HR’s in all of the histologic subtypes, except for pleomorphic, where
Whites have the highest HR.
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Discussion

!

This study of 4,268 patients diagnosed with RMS, ages ranging from birth to 98
years, revealed that race may play an important role in RMS incidence and survival. We
found that ethnic minorities were more likely than Whites to have mixed-type, spindle
cell, or alveolar histologies, regional or distant metastasis, unfavorable prognostic tumor
site, and no treatment. Ethnic minorities were also less likely than Whites to receive
multimodal treatment of radiation and surgery. The disparity in treatment methods in our
study could be due to underrepresentation of these populations in RMS clinical trials,
and therefore hesitance from physicians to administer these therapies in ethnic
minorities [8,9,10]. Current literature is inconclusive with some reporting statistically
significant differences in these characteristics by race [7,11,17], and others reporting no
differences by race [5].
Blacks were found to have higher RMS incidence rates over the study period
than Whites. APC in Blacks trended towards an increase, but was not statistically
significant. Overall RMS APC and APC in Whites did have a statistically significant trend
downwards, meaning that RMS incidence overall and for Whites is declining. Previous
studies have found that while males and Black children have higher incidence rates of
RMS [7,12], there were no differences in survival by gender or race, for both children
and adults [3,5,11,17]. Although adjusted overall survival was not predicted by race in
our study, stratification by age group did uncover significant racial survival
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disparities, particularly among children diagnosed with RMS. One study did report that
Hispanic children seemed to have lower 5-year survival rates than white children for
certain histologic subtypes [7], though these results were based on a relatively small
number of children in each category, so caution must be taken in interpreting these
results.
In our study Blacks were found to have a 14% increase in risk for mortality that
trended towards significance (p-value: 0.06) in the full adjusted model. When the
analysis was stratified by diagnostic era, the risk for mortality increased to 18% (pvalue: 0.04) in the 1990-2013 diagnostic period. This difference could be the result of an
increase in sample size, due to the expansion of the SEER registries over the second
diagnostic period [19].
Some possible explanations for our findings could be differences in racial/ethnic
immunization schedule compliance, or differences in genetic predisposition. It has been
found that children diagnosed with RMS are five-times more likely to have incomplete
immunization schedules when compared to controls [2]; however, this study did not
analyze race as a predictor for immunization schedule compliance. Non-white race has
been found to be a significant predictor of non-compliance to immunization schedules in
other studies [20]. This could also aid in explaining why a greater proportion of ethnic
minority children were diagnosed with RMS than white children our study.
Studies have estimated that ~5% of RMS cases are associated with genetic
predisposition to several different conditions, such as TP53 mutations (Li-Fraumeni
syndrome), Costello syndrome, neurofibromatosis, and Beckwith-Wiedeman syndrome
[1,6,7]. One study in endometrial cancer has found that the incidence in p53

!

12!

!
overexpression, as a result of TP53 mutations, was higher in Black cases than White
cases in both early and advanced disease, and that survival was worse in Blacks than
Whites with similar disease stage and p53 expression [22]. These results may help to
explain racial disparities in cancers associated with TP53 mutations. TP53 mutations
have been analyzed in childhood cases of RMS [22], and results have shown that
patients that carry the TP53 mutation are predisposed to developing RMS at a younger
age. In this study, a greater percentage of ethnic minority cases were children,
compared to White cases, with Hispanics containing the highest percentage of children
(68%). The association between RMS, TP53 mutations, and race has not yet been
described, but future studies on the topic may aid in explaining why ethnic minorities
have several significant differences in clinical presentation of RMS than Whites [17].
A primary strength of using the SEER dataset is that it provides a large sample
size of RMS cases, over a large period of time, which creates adequate statistical power
for analysis of this rare malignancy. Data gathered from SEER also provide important
information on clinical characteristics and treatment methods. Another strength of this
study is the inclusion of Hispanics and other minority races.
This study is not without limitations. Survival estimates and incidence rates for
Whites and Blacks from the SEER 9 database may contain Hispanic data for cases
diagnosed prior to the SEER 13 expansion in 1992. Analyses on the effect of treatment
are also limited by the fact that SEER does not collect information on chemotherapy,
which is a mainstay of RMS management [3,4,8-10,19]; therefore we were unable to
account for the treatment effect of chemotherapy in the current study. Information on
diagnoses reported to SEER is rendered by a multitude of oncologists and pathologists
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with variable equipment and expertise, and there is no central pathological review of this
information. However, in 1995 the International Classification of RMS (ICR) was
established, improving the reproducibility of RMS classification, as well as outcome
prediction [7]. Follow-up for cases in the SEER database is passive, and incomplete
data is often a problem [5]; this analysis excluded 12 patients (0.3%) due to incomplete
follow-up data, but it is unlikely this affected the results. Our analysis spans a 40-year
time period, and within this time period great progress has been made in areas of
diagnosis and treatment of RMS. It is possible that some RMS NOS and pleomorphic
cases diagnosed prior to the establishment of the IRC were misdiagnosed, and are
actually not RMS [3]. The spindle cell variant of RMS was not described until efforts in
1992 [23] and 1993 [24] made the distinction of this subtype from the more common
embryonal RMS. Therefore, it is possible that diagnoses of embryonal RMS made prior
to these two studies may actually be cases of spindle cell RMS [15]. Spindle cell RMS is
exceedingly rare and most cases of this subtype occur in the favorable prognostic site
of the paratesticular region [15,23,24], so any affect on the results of this study is likely
to be small to negligible.
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Conclusion
Racial disparities in RMS are not yet completely understood, but it is
thought to be a result of both environmental and socioeconomic factors [11,14].
Our study highlights the racial disparities in RMS presentation, incidence, and
survival in ethnic minorities. Ethnic minorities are at an increased risk for
developing RMS, and children of ethnic minorities have lower survival rates than
White children within this study. While RMS incidence is significantly declining
overall, and in Whites, it is trending upwards for ethnic minorities. Differences in
incidence rates and clinical characteristics in ethnic minority populations in this
study may point towards a genetic component in RMS. Future studies should aim
at describing immunization compliance in ethnic minority children with RMS,
compared to White children with RMS, as well as describing the link between
TP53 mutations and RMS by race.!
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Table 1. Characteristics of RMS Patients During Period of 1973-2013 Stratified by Race
Total
N=4,268
N (%)
Age at diagnosis
Child (0-19 years)
Adult (>19 years)
Median ± SD
Sex
Female
Male
Diagnostic period†
1973-1989
1990-2013
Geographic region
Northeast
Midwest
South
West
Histologic type
Pleomorphic
Mixed-Type
Embryonic
Spindle Cell
Alveolar
RMS (NOS)
Tumor behavior
Localized
Regional metastasis
Distant metastasis
Un-staged
Anatomical site
Head and neck‡
Trunk
Genitourinary⊺
Orbital
Extremity
Kidney
Prostate
Bladder
Biliary tract
Other/Unknown
Prognostic site
Favorable
Unfavorable
Unknown
Treatment
No treatment
Radiation only
Surgery only
Radiation & Surgery
Either or both
treatments unknown
Vital status
Alive
Dead

NHW
N=2,601
N (%)

NHB
N=626
N (%)

Hispanic
N=664
N (%)

Other*
N=377
N (%)

2427 (56.9)
1841 (43.1)
16 ± 26.5

1395 (53.6)
1206 (46.4)
17 ± 28.2

357 (57.0)
269 (43.0)
16 ± 23.9

452 (68.0)
212 (32.0)
12 ± 21.0

223 (59.2)
154 (40.8)
16 ± 24.2

1858 (43.5)
2410 (56.5)

1110 (42.7)
1491 (57.3)

288 (46.0)
338 (54.0)

302 (45.5)
362 (54.5)

158 (41.9)
219 (58.1)

897 (21.0)
3371 (79.0)

719 (27.6)
1882 (72.4)

87 (13.9)
539 (86.1)

0 (0.0)
664 (100)

91 (24.1)
286 (75.9)

659 (15.4)
675 (15.8)
686 (16.1)
2249 (52.7)

479 (18.4)
548 (21.1)
394 (15.2)
1180 (45.4)

79 (12.6)
104 (16.6)
233 (37.2)
210 (33.6)

65 (9.8)
10 (1.5)
40 (6.0)
549 (82.7)

36 (9.5)
13 (3.5)
18 (4.8)
310 (82.3)

395 (9.3)
72 (1.7)
1698 (39.8)
85 (2.0)
974 (22.8)
1044 (24.5)

271 (10.4)
40 (1.5)
1036 (39.8)
41 (1.6)
523 (20.1)
690 (26.5)

48 (7.7)
14 (2.2)
259 (41.4)
16 (2.6)
158 (25.2)
131 (20.9)

41 (6.2)
15 (2.3)
261 (39.3)
23 (3.5)
198 (29.8)
126 (19.0)

35 (9.3)
3 (0.80)
142 (37.7)
5 (1.3)
95 (25.2)
97(25.7)

1264 (29.6)
1271 (29.8)
1234 (28.9)
499 (11.7)

788 (30.3)
750 (28.8)
695 (26.7)
368 (14.2)

195 (31.2)
183 (29.2)
201 (32.1)
47 (7.5)

166 (25.0)
217 (32.7)
230 (34.6)
51 (7.7)

115 (30.5)
121 (32.1)
108 (28.7)
33 (8.8)

1073 (25.1)
1247 (29.2)
662 (15.5)
199 (4.7)
789 (18.5)
16 (0.4)
94 (2.2)
112 (2.6)
28 (0.7)
48 (1.1)

641 (24.6)
767 (29.5)
368 (14.2)
127 (4.9)
501 (19.3)
13 (0.5)
63 (2.4)
69 (2.7)
15 (0.6)
37 (1.4)

141 (22.5)
173 (27.6)
145 (23.2)
26 (4.2)
110 (17.6)
1 (0.2)
7 (1.1)
16 (2.6)
2 (0.3)
5 (0.8)

196 (29.5)
187 (28.2)
101 (15.2)
24 (3.6)
110 (16.6)
1 (0.2)
15 (2.3)
18 (2.7)
9 (1.4)
3 (0.5)

95 (25.2)
120 (31.8)
48 (12.7)
22 (5.8)
68 (18.0)
1 (0.3)
9 (2.4)
9 (2.4)
2 (0.5)
3 (0.8)

1508 (35.3)
2712 (63.5)
48 (1.1)

891 (34.3)
1673 (64.3)
37 (1.4)

250 (39.9)
371 (59.3)
5 (0.8)

236 (35.5)
425 (64.0)
3 (0.5)

131 (34.8)
243 (64.5)
3 (0.80)

637 (14.9)
973 (22.8)
1215 (28.5)
1300 (30.5)
143 (3.4)

370 (14.2)
553 (21.3)
766 (29.5)
817 (31.4)
95 (3.7)

92 (14.7)
153 (24.4)
182 (29.1)
175 (28.0)
24 (3.8)

113 (17.0)
180 (27.1)
172 (25.9)
184 (27.7)
15 (2.3)

62 (16.5)
87 (23.1)
95 (25.2)
124 (32.9)
9 (2.4)

P-value

<.0001

0.29
<.0001
<.0001

<.0001

<.0001

0.0001

0.05

0.01

0.15
2519 (59.0)
1749 (41.0)

1547 (59.5)
1054 (40.5)

359 (57.4)
267 (42.6)

407 (61.3)
257 (38.7)

206 (54.5)
172 (45.5)

Abbreviations: SD, standard deviation; HR, hazard ratio; RMS, rhabdomyosarcoma; NOS, not otherwise specified; NHW,
non-hispanic white; NHB, non-hispanic black; SEER, Surveillance, Epidemiology, and End Results
*Includes American Indian/Alaskan Native, Asian/Pacific Islander, unspecified and unknown.
†The SEER program has expanded since its establishment to cover 9.5% (SEER 9), 13.8% (SEER 13) and 30% (SEER
18) of the total United States population; therefore, more patients were registered in 1990-2013 period. The latter time
period also represents a longer time in years.
‡Head and neck, excluding orbital tumors
⊺Genitourinary, excluding kidney, prostate, and bladder tumors
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Table 2: Multivariate Cox Proportional Hazard Analysis of RMS During Period of 1973-2013
Period of 1973-2013
N = 4,268
HR (95% CI)
P

n
Age at diagnosis
Children
2427
Ref.
Adults
1841
2.19 (1.97-2.44) <.0001
Sex
Female
1858
Ref.
Male
2410
0.97 (0.88-1.07)
0.57
Race/ethnicity
NHW
2601
Ref.
NHB
626
1.14 (0.99-1.31)
0.06
Hispanic
664
1.05 (0.91-1.22)
0.52
Other
377
1.13 (0.96-1.34)
0.15
Diagnostic period
1973-1989
897
Ref.
1990-2013
3371
0.63 (0.56-0.71) <.0001
Geographic region
Northeast
659
Ref.
Midwest
675
1.35 (1.13-1.61) 0.0009
South
685
1.14 (0.95-1.37)
0.10
West
2249
1.22 (1.04-1.41)
0.01
Histologic type
Embryonic
1698
Ref.
Pleomorphic
395
1.59 (1.32-1.92) <.0001
Mixed-type
72
1.80 (1.26-2.57)
0.001
Spindle cell
85
0.94 (0.59-1.52)
0.81
Alveolar
974
1.37 (1.21-1.57) <.0001
RMS (NOS)
1044
1.51 (1.33-1.73) <.0001
Tumor behavior
Localized
1264
Ref.
Regional
1271
1.96 (1.68-2.28) <.0001
Distant
1234
4.56 (3.92-5.30) <.0001
Un-staged
499
2.31 (1.91-2.79) <.0001
Prognostic site
Favorable site
1508
Ref.
Unfavorable site
2712
1.38 (1.23-1.55) <.0001
Unknown
48
2.19 (1.48-3.23) <.0001
Treatment
No treatment
637
Ref.
Radiation only
973
0.64 (0.56-0.74) <.0001
Surgery only
1215
0.57 (0.49-0.67) <.0001
Radiation & surgery
1300
0.48 (0.41-0.55) <.0001
Either or both
143
0.71 (0.55-0.92)
0.001
treatments unknown
Abbreviations: CI, confidence interval; HR, hazard ratio; N, Total number; n, cell number; P, P-value; RMS,
rhabdomyosarcoma; NOS, not otherwise specified; NHW, non-hispanic white; NHB, non-hispanic black
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Table 3: Multivariate Cox Proportional Hazard Analysis of RMS Stratified Analysis by
Diagnostic Period
Period of 1973-1989
N = 897
HR (95% CI)
P

Period of 1990-2013
N = 3,371
HR (95% CI)
P

n
n
Age at diagnosis
Children
480
Ref.
1947
Ref.
Adults
417
2.56 (2.06-3.18) <.0001
1424
2.11 (1.85-2.39)
<.0001
Sex
Female
372
Ref.
1486
Ref.
Male
525
1.11 (0.92-1.34)
0.26
1885
0.93 (0.83-1.04)
0.18
Race/ethnicity
NHW
719
Ref.
1882
Ref.
NHB
87
1.17 (0.86-1.61)
0.32
539
1.18 (1.01-1.38)
0.04
Hispanic
0
NA
---664
1.07 (0.91-1.24)
0.42
Other
91
1.09 (0.80-1.50)
0.58
286
1.15 (0.95-1.41)
0.16
Diagnostic period
1973-1989
------------1990-2013
------------Geographic region
Northeast
153
Ref.
506
Ref.
Midwest
318
1.36 (0.98-1.90)
0.07
357
1.26 (1.00-1.59)
0.05
South
53
0.94 (0.56-1.56)
0.80
632
1.17 (0.96-1.44)
0.13
West
373
1.24 (0.89-1.73)
0.10
1876
1.20 (1.00-1.43)
0.05
Histologic type
Embryonic
391
Ref.
1307
Ref.
Pleomorphic
60
0.96 (0.63-1.46)
0.83
335
1.97 (1.58-2.45)
<.0001
Mixed-type
10
1.79 (0.79-4.10)
0.17
62
1.83 (1.23-2.72)
0.003
Spindle cell
0
N/A
85
1.00 (0.62-1.61)
1
Alveolar
115
1.00 (0.75-1.34)
0.99
859
1.56 (1.34-1.82)
<.0001
RMS (NOS)
321
1.30 (1.03-1.64)
0.03
723
1.63 (1.38-1.93)
<.0001
Tumor behavior
Localized
327
Ref.
937
Ref.
Regional
194
1.75 (1.32-2.33) 0.0001
1077
1.98 (1.65-2.39)
<.0001
Distant
213
4.33 (3.31-5.68) <.0001
1021
4.65 (3.86-5.59)
<.0001
Un-staged
163
2.13 (1.57-2.90) <.0001
336
2.30 (1.80-2.95)
<.0001
Prognostic site
Favorable site
283
Ref.
1225
Ref.
Unfavorable site
593
1.61 (1.28-2.03) <.0001
2119
1.29 (1.13-1.48)
0.0003
Unknown
21
2.46 (1.33-4.53)
0.004
27
2.54 (1.51-4.30)
0.0005
Treatment
No treatment
116
Ref.
521
Ref.
Radiation only
160
0.94 (0.69-1.23)
0.70
813
0.57 (0.49-0.67)
<.0001
Surgery only
289
0.56 (0.41-0.78) 0.0004
926
0.59 (0.50-0.71)
<.0001
Radiation & surgery
270
0.59 (0.43-0.80) 0.0007
1030
0.44 (0.37-0.52)
<.0001
Either or both
62
1.05 (0.66-1.66)
0.84
81
0.56 (0.39-0.80)
0.001
treatments unknown
Abbreviations: CI, confidence interval; HR, hazard ratio; N, Total number; n, cell number; P, P-value; RMS,
rhabdomyosarcoma; NOS, not otherwise specified; NHW, non-hispanic white; NHB, non-hispanic black !

18
!

Table 4. Multivariate Cox Proportional Hazards Analysis of RMS During Period of 19732013, Stratified by Age
Child
N = 2,427
HR (95% CI)

Adult
N = 1,841
HR (95% CI)

n
P
n
P
Sex
Female
998
Ref.
860
Ref.
Male
1429
1.06 (0.92-1.22)
0.42
981
0.93 (0.81-1.06)
0.27
Race/ethnicity
NHW
1395
Ref.
1206
Ref.
NHB
357
1.05 (0.86-1.29)
0.63
269
1.20 (0.99-1.45)
0.07
Hispanic
452
1.05 (0.86-1.29)
0.65
212
1.07 (0.86-1.33)
0.55
Other
223
1.31 (1.03-1.66)
0.03
154
0.98 (0.77-1.24)
0.85
Diagnostic period
1973-1989
480
Ref.
417
Ref.
1990-2013
1947
0.62 (0.52-0.74) <.0001
1424
0.63 (0.54-0.75) <.0001
Geographic region
Northeast
347
Ref.
312
Ref.
Midwest
382
1.29 (0.98-1.69)
0.07
293
1.40 (1.10-1.77)
0.006
South
396
1.22 (0.92-1.61)
0.17
289
1.10 (0.86-1.41)
0.46
West
1302
1.27 (1.00-1.60)
0.05
947
1.17 (0.96-1.43)
0.11
Histologic type
Embryonic
1348
Ref.
350
Ref.
Pleomorphic
18
2.14 (1.10-4.19)
0.03
377
1.34 (1.07-1.67)
0.01
Mixed-type
36
1.73 (1.03-2.92)
0.04
36
1.63 (1.00-2.67)
0.05
Spindle cell
45
0.98 (0.48-1.99)
0.95
40
0.83 (0.44-1.58)
0.57
Alveolar
682
1.67 (1.42-1.99) <.0001
293
0.99 (0.79-1.23)
0.91
RMS (NOS)
299
1.58 (1.28-1.95) <.0001
745
1.27 (1.05-1.53)
0.01
Tumor behavior
Localized
728
Ref.
536
Ref.
Regional metastasis
773
2.06 (1.63-2.62) <.0001
498
1.86 (1.51-2.28) <.0001
Distant metastasis
667
5.07 (4.02-6.38) <.0001
567
3.95 (3.22-4.84) <.0001
Un-staged
259
2.66 (1.99-3.57) <.0001
240
2.00 (1.55-2.58) <.0001
Prognostic site
Favorable site
985
Ref.
523
Ref.
Unfavorable site
1428
1.53 (1.30-1.81) <.0001
1284
1.26 (1.07-1.49)
0.006
Unknown
14
3.00 (1.46-6.16)
0.003
34
1.96 (1.22-3.16)
0.006
Treatment
No treatment
262
Ref.
375
Ref.
Radiation only
708
0.69 (0.56-0.84) 0.0003
265
0.63 (0.51-0.77) <.0001
Surgery only
564
0.62 (0.48-0.79) 0.0001
651
0.52 (0.43-0.64) <.0001
Radiation & surgery
820
0.53 (0.43-0.66) <.0001
480
0.44 (0.36-0.54) <.0001
Either or both
73
0.95 (0.65-1.38)
0.78
70
0.60 (0.43-0.85)
0.004
treatments unknown
Abbreviations: CI, confidence interval; HR, hazard ratio; N, Total number; n, cell number; P, P-value; RMS,
rhabdomyosarcoma; NOS, not otherwise specified; NHW, non-hispanic white; NHB, non-hispanic black!
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Table 5. Multivariate Cox Proportional Hazards Analysis of RMS During Period of 1973-2013, Stratified by Race/Ethnicity
NHW
N = 2,601
HR (95% CI)

NHB
N = 626
HR (95% CI)

Hispanic
N = 664
HR (95% CI)

Other
N = 377
HR (95% CI)

n
P
n
P
n
P
n
P
Age
Children
1395
Ref.
357
Ref.
452
Ref.
223
Ref.
Adults
1206
2.26 (1.96-2.61) <.0001
269
2.86 (2.16-3.79) <.0001
212
2.25 (1.71-2.97) <.0001
154
1.48 (1.04-2.12)
0.03
Sex
Female
1110
Ref.
288
Ref.
302
Ref.
158
Ref.
Male
1491
1.05 (0.93-1.19)
0.43
338
1.09 (0.85-1.41)
0.49
362
0.71 (0.55-0.91)
0.008
219
0.86 (0.62-1.18)
0.34
Diagnostic Period
1973-1989
719
Ref.
87
Ref.
0
Ref.
91
Ref.
1990-2013
1882
0.63 (0.54-0.72) <.0001
539
0.57 (0.40-0.80)
0.001
664
NE
---286
0.67 (0.46-0.98)
0.04
Geographic region
Northeast
479
Ref.
79
Ref.
65
Ref.
36
Ref.
Midwest
548
1.42 (1.16-1.74) 0.0008
104
1.24 (0.75-2.05)
0.40
10
1.43 (0.53-3.89)
0.48
13
2.00 (0.68-5.89)
0.21
South
394
1.18 (0.94-1.49)
0.15
233
1.24 (0.80-1.90)
0.33
40
0.68 (0.34-1.39)
0.29
18
1.07 (0.37-3.11)
0.90
West
1180
1.26 (1.05-1.52)
0.01
210
1.21 (0.78-1.88)
0.41
549
0.96 (0.62-1.49)
0.86
310
1.49 (0.74-3.00)
0.27
Histologic type
Embryonic
1036
Ref.
259
Ref.
261
Ref.
142
Ref.
Pleomorphic
271
1.45 (1.14-1.84)
0.003
48
1.76 (1.03-3.02)
0.04
41
1.87 (1.08-3.22)
0.02
35
2.83 (1.51-5.30)
0.001
Mixed-type
40
2.07 (1.28-3.34)
0.003
14
1.53 (0.70-3.36)
0.29
15
1.46 (0.65-3.29)
0.36
3
3.37 (0.45-25.25)
0.24
Spindle cell
41
0.69 (0.31-1.56)
0.37
16
0.91 (0.33-2.52)
0.85
23
1.20 (0.54-2.65)
0.65
5
1.29 (0.16-10.15)
0.81
Alveolar
523
1.33 (1.12-1.57)
0.001
158
1.56 (1.11-2.19)
0.01
198
1.20 (0.85-1.67)
0.30
95
2.07 (1.33-3.23)
0.001
RMS (NOS)
690
1.44 (1.21-1.71) <.0001
131
1.44 (1.02-2.04)
0.04
126
1.78 (1.24-2.56)
0.002
97
2.19 (1.38-3.48)
0.002
Tumor behavior
Localized
788
Ref.
195
Ref.
166
Ref.
115
Ref.
Regional metastasis
750
1.91 (1.57-2.32) <.0001
183
2.71 (1.80-4.07) <.0001
217
1.97 (1.28-3.01)
0.002
121
1.69 (1.05-2.72)
0.03
Distant metastasis
695
4.58 (3.77-5.55) <.0001
201
5.69 (3.81-8.48) <.0001
230
4.62 (3.02-7.06) <.0001
108
3.68 (2.27-5.97) <.0001
Un-staged
368
2.14 (1.70-2.70) <.0001
47
4.05 (2.33-7.03) <.0001
51
2.25 (1.26-4.02)
0.006
33
3.02 (1.54-5.92)
0.001
Prognostic site
Favorable site
891
Ref.
250
Ref.
236
Ref.
131
Ref.
Unfavorable site
1673
1.48 (1.27-1.72) <.0001
371
1.37 (1.02-1.84)
0.04
425
1.31 (0.97-1.78)
0.08
243
1.13 (0.77-1.65)
0.53
Unknown
37
2.55 (1.62-3.99) <.0001
5
0.51 (0.13-2.01)
0.34
3
8.89(1.95-40.57)
0.005
3
1.02 (0.21-4.95)
0.99
Treatment
No treatment
370
Ref.
92
Ref.
113
Ref.
62
Ref.
Radiation only
553
0.65 (0.53-0.78) <.0001
153
0.67 (0.47-0.95)
0.03
180
0.59 (0.41-0.85)
0.005
87
0.54 (0.34-0.85)
0.008
Surgery only
766
0.52 (0.42-0.63) <.0001
182
0.82 (0.55-1.22)
0.32
172
0.68 (0.45-1.04)
0.07
95
0.39 (0.24-0.65) 0.0002
Radiation & surgery
817
0.46 (0.38-0.56) <.0001
175
0.53 (0.36-0.79)
0.002
184
0.57 (0.39-0.84)
0.004
124
0.29 (0.18-0.47) <.0001
Either or both
95
0.83 (0.60-1.14)
0.24
24
0.50 (0.26-0.99)
0.05
15
0.70 (0.32-1.51)
0.36
9
0.32 (0.11-0.94)
0.04
treatments unknown
Abbreviations: CI, confidence interval; HR, hazard ratio; N, Total number; n, cell number; P, P-value; RMS, rhabdomyosarcoma; NOS, not otherwise specified; NHW, non-hispanic
white; NHB, non-hispanic black; NE, not estimable!
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Figure 1. RMS Incidence Rates from 1973-2013*
*Overall, White, and Black rates from SEER 9 incidence data; Hispanic rates from SEER 13 data.!
⊺Race/Ethnicity groups are represented by the following symbols: Overall – blue diamonds and a solid line; Whites – red
squares and a dashed line; Blacks – green triangles and a dotted line; Hispanics – purple crosses and dotted/dashed line.
⋄Data are shown as: Annual Percentage Change (95% Confidence Interval).
†Rates are per 100,000 and age-adjusted to the 2000 US Std Population standard.
‡Percentage changes were calculated using 1 year for each end point; Annual Percentage Changes were calculated
using weighted least squares method.!
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Figure 2. Adjusted RMS Survival, by Race*
*Race/Ethnicity groups are represented by the following symbols: Overall – blue line; Whites – red line; Blacks – green
line; Hispanics – purple line; Others – orange line. !
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Figure 3. RMS Survival in Children and Adults, by Race*

!

*Race/Ethnicity groups are represented by the following symbols: Overall Children – solid blue line; Overall Adults –
dashed blue line; White Children – solid red line; White Adults – dashed red line; Black Children – solid green line; Black
Adults – dashed green line; Hispanic Children – solid purple line; Hispanic Adults – dashed purple line; Other Children –
solid orange line; Other Adults – dashed orange line.!
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11/1/2016
Heather Tinsley
Epidemiology and Biostatistics
Tampa, FL 33612
RE: Not Human Subjects Research Determination
IRB#: Pro00028332
Title: Rhabdomyosarcoma Incidence and Survival in Whites, Blacks, and Hispanics from 19732013: Analysis from the Surveillance, Epidemiology and End Results Program
Dear Ms. Tinsley:
The Institutional Review Board (IRB) has reviewed your application and determined the
activities do not meet the definition of human subjects research. Therefore, this project is not
under the purview of the USF IRB and approval is not required. If the scope of your project
changes in the future, please contact the IRB for further guidance.
All research activities, regardless of the level of IRB oversight, must be conducted in a manner
that is consistent with the ethical principles of your profession. Please note that there may be
requirements under the HIPAA Privacy Rule that apply to the information/data you will utilize.
For further information, please contact a HIPAA Program administrator at 813-974-5638.
We appreciate your dedication to the ethical conduct of research at the University of South
Florida. If you have any questions regarding this matter, please call 813-974-5638.
Sincerely,

E. Verena Jorgensen, M.D., Chairperson
USF Institutional Review Board
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